Hematologic Malignancy
Transformed B-Cell Non-Hodgkin Lymphoma
CI-CAN-00004141Explore in graph →
Hematologic27 active trials
- NCIt
- C216069
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00004141Explore in graph →
Clinical trials
42 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (6)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | terminated | Phase 1 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Aug 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Aug 3, 2025source: clinicaltrials